TT-232

DB12088InvestigationalSmall molecule

Tln 232 is under investigation in clinical trial NCT00422786 (Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma).

Formula / weight: C₄₅H₅₈N₁₀O₉S₂ · 947.14 g/mol (avg)
Also known as: D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2 (disulfide bridge: 2-6)
Code names: TLN-232

Resolves to

Compound

UNII49D4Q4254ZCAS147159-51-1ChEMBLCHEMBL539934PubChem6918265

Structure

InChIKeySNAJPQVDGYDQSW-DYCFWDQMSA-NSMILES

C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=CC=CC=C23)C(=O)N[C@@H](CCCCN)C(=O)N1)C(N)=O

Targets

P14618PKM

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with TT-232, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account